BioSpace News Archive

Bacainn Therapeutics, Inc. today presented results at the European Crohn’s and Colitis Organisation’s 2021 Virtual Congress from a Phase 1 study that showed its lead asset BT051 was safe and well-tolerated in healthy adults. BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinical development for the treatment of inflammatory bowel disease (IBD), which impacts as many as 6.8 million people in the United States and Europe

ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC).

Median Technologies, announces the publication date for its 2021 half year results and its Q3, 2021 business performance :

OSE Immunotherapeutics announced a €10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank.

Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies, announced its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test is the first quantitative COVID-19 IgG antibody test to receive U.S. Food and Drug Administration Emergency Use Authorization.

Surgical robots play a vital role in surgery, particularly in handling surgical devices precisely over small incisions for different surgical procedures.

Jaguar Health, Inc. announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 for a third time due to a lack of quorum.

Sensient Technologies Corporation will hold its conference call to discuss 2021 second quarter results at 8:30 a.m. CDT on Friday, July 23, 2021.

Ocuphire Pharma, Inc., announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Amanda Providakes in connection with her employment with the Company effective on July 6, 2021.

iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or the “Company”) is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the “Exchange”) of iCo’s proposed business combination (the “Transaction”) with Satellos Bioscience Inc. (“Satellos”).